BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Clinical Trial Buddy Program Among Innovative Support Offerings From The College Entrance Examination Board


2/23/2006 10:48:45 AM

NEW YORK, Feb. 23 /PRNewswire/ -- Colon cancer patients considering participation in a clinical trial can now access a first-of-its-kind peer-to- peer support system, the Buddy Program, the Colon Cancer Alliance (CCA) announced today. As a result of this innovation, an experienced mentor will provide guidance to newly diagnosed patients about how to prepare for clinical trials and understand the process. The announcement comes as the CCA marks the seventh Annual National Colorectal Cancer Awareness Month in March.

Although more Americans have become aware of colon cancer in recent years, one person still dies of the disease every nine minutes. Research shows the mortality rate will likely decrease if patients and caregivers have a better understanding of how to treat the disease. In fact, thousands of clinical trials are available for patients to try new, experimental and investigational drugs. But fewer than five percent of adult cancer patients currently choose to participate in them.

"For the first time, colorectal cancer patients will have the opportunity to be educated about clinical trials by someone who has just been in their shoes," said Amy Kelly, Co-Founder and Executive Director of the CCA. "We expect that the intimacy of this experience will encourage more patients to join trials. As more people participate, we will develop the necessary research to find the best treatments for the disease."

Since 1995, participation in clinical trials has declined due to long- standing fear, apprehension and skepticism. Doctors also may not mention trials as an option and access problems still exist. To help maximize the CCA's Buddy Program and address some of these problems, all potential mentors will undergo training to ensure that they can offer the most appropriate guidance. The clinical trial component will expand an existing program in which colon cancer survivors, their families and friends are able to speak to others who have "been there." These buddies provide a personal perspective on coping with side effects, treatment options, life after a colostomy and many other emotional issues. Those interested in learning more about the buddy program can visit http://www.ccalliance.org.

The CCA also has implemented additional educational initiatives as a result of feedback from patients and caregivers. This year the nonprofit plans to add live operators to its help-line, develop patient education materials in Spanish, distribute more free materials to doctors and hospitals, add more guest speakers to on-line chats, continue to grow its local chapter program, Voices, and expand colon cancer conference sites and locations throughout the United States. The Alliance also will make press kits available via their Web site for local groups or individuals wishing to promote National Colorectal Awareness Month.

The Colon Cancer Alliance

The Colon Cancer Alliance (CCA) is a national patient advocacy organization, with chapters located across the country, and the official patient support partner of Katie Couric's National Colorectal Cancer Research Alliance (NCCRA). CCA is dedicated to ending the suffering caused by colorectal cancer. The Colon Cancer Alliance brings the voice of survivors to battle colon cancer through patient support, education, research and advocacy. CCA invites any and all organizations, government agencies, members of the medical community and individuals impacted by this disease to add their voices by joining CCA in their determination to eradicate colorectal cancer. The Colon Cancer Alliance educational programs are made possible through corporate grants or charitable donations from Amgen, Antigenics, Bristol-Myers Squibb Oncology, Ethicon-Endo Surgery, Genentech BioOncology, GlaxoSmithKline, Inkine, Myriad Genetics, Pfizer, Roche, and Sanofi-Aventis. The Colon Cancer Alliance's toll-free helpline is 1-877-422-2030 or visit the Web site at http://www.ccalliance.org.

Colon Cancer Alliance

CONTACT: Amy E. Kelly of Colon Cancer Alliance, +1-954-341-0212,akelly@ccalliance.org; or Karen Pasternack of Porter Novelli,+1-212-601-8049, kpasternack@porternovelli.com, for Colon Cancer Alliance


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->